Learn about the values that drive us
Menarini are supporting ongoing education for HCPs. Please explore the regularly updated on-demand webinars.
Click on a therapy area to learn more
This site is intended for UK healthcare professionals only and contains promotional information. Please visit the MHRA Yellowcard site to report an Adverse Event.
Subscribe to our mailing list to receive tailored communications on upcoming webinars, product updates and HCP events
PP-MN-UK-0660 September 2023
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to www.menarini.co.uk where you will be able to access reference information on A. Menarini Farmaceutica Internazionale SRL's medicines.
*The ABPI Code definition for healthcare professional is any member of the medical, dental, pharmacy or nursing profession and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-MN-UK-0665 September 2023
Disclaimer
You are now leaving an A. Menarini Farmaceutica Internazionale SRL (AMFI) website.
We are not responsible for the contents, processing of personal data of any linked site or any link contained in a linked website, or any changes or updates to such websites.
This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by AMFI.
Job code: PP-MN-UK-0543 February 2024
INVOKANA®(canagliflozin) has proven efficacy in glycaemic control, renal and CV* protection1-4
INVOKANA®(canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, please refer to section 4.4, 4.5 and 5.1 of the Invokana SmPC.
1. Invokana Summary of Product Characteristics, 2. Zaccardi F et al. Diabetes Obes Metab 2016; 18(8): 783-794, 3. Perkovic V et al. N Engl J Med 2019; 380(24): 2295-2306, 4. Neal B et al. N Engl J Med 2017; 377(7): 644-657, *cardiovascular
Supporting the Fight Against Antimicrobial Resistance (AMR)
Prescribing Information can be found under Featured Medicines
Menarini becomes exclusive distributor for INVOKANA® (canagliflozin) and VOKANAMET® (fixed-dose combination of canagliflozin and metformin) in the UK. Learn more about the treatment for Type 2 Diabetes
Learn more about our Anti-infective portfolio, and the work we do to support the fight against Antimicrobial Resistance (AMR).
Invokana®(canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
TENKASI is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
QUOFENIX is indicated (in Great Britain) for the treatment of the following infections in adults:
Because of the risk of prolonged, disabling and potentially irreversible serious adverse drug reactions, this product must only be prescribed when other antibiotics that are commonly recommended for these infections are inappropriate.
VABOREM is indicated in adults for the treatment of:
We launched in the UK in 1999 with a passion for improving patient outcomes. We've come a long way but there's always more to be done. Click below to learn more about us.
PP-MN-UK-0582 November 2024